The following treatments were administered over a 7-day period: lornoxicam 8mg quick-release formulation or diclofenac potassium 50mg. On day 1, patients received in the clinic, no later than 2pm ...

The goal of the TIGHT K trial was to evaluate if prescribing relaxed control of potassium levels and only giving supplements in the rare event that levels became pathologically low was equally as ...

Diclofenac potassium was well tolerated ... It belongs to the phenylacetic acid class, of which diclofenac sodium (Voltaren®, an enteric-coated tablet) was first marketed in Japan in 1974.